Literature DB >> 11782030

Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections.

H Schäfer1, H H Müller.   

Abstract

A method is presented which allows us to adapt the sample size as well as the number and time points of interim analyses to the treatment difference observed at an interim look during the course of a clinical trial with censored survival time as the endpoint. The method allows the inclusion of data inspections during the course of the trial and redesign of the trial on the basis of the observed treatment difference without affecting the type I error risk. Formulae for recalculating the required number of events and the number of further patients to be randomized as a function of the observed hazard rates and the detectable hazard ratio are given. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11782030     DOI: 10.1002/sim.1136

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  [Modern study designs and analysis methods in clinical research].

Authors:  J Gerß; M Eveslage; A Faldum; R Schmidt
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

2.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

Review 3.  Quantifying treatment differences in confirmatory trials under non-proportional hazards.

Authors:  José L Jiménez
Journal:  J Appl Stat       Date:  2020-09-03       Impact factor: 1.416

4.  Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.

Authors:  Dominic Magirr; Thomas Jaki; Franz Koenig; Martin Posch
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

5.  Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.

Authors:  Jannik Feld; Andreas Faldum; Rene Schmidt
Journal:  Stat Methods Med Res       Date:  2021-10-12       Impact factor: 3.021

6.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

7.  Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.

Authors:  Yaseen M Arabi; Adel Alothman; Hanan H Balkhy; Abdulaziz Al-Dawood; Sameera AlJohani; Shmeylan Al Harbi; Suleiman Kojan; Majed Al Jeraisy; Ahmad M Deeb; Abdullah M Assiri; Fahad Al-Hameed; Asim AlSaedi; Yasser Mandourah; Ghaleb A Almekhlafi; Nisreen Murad Sherbeeni; Fatehi Elnour Elzein; Javed Memon; Yusri Taha; Abdullah Almotairi; Khalid A Maghrabi; Ismael Qushmaq; Ali Al Bshabshe; Ayman Kharaba; Sarah Shalhoub; Jesna Jose; Robert A Fowler; Frederick G Hayden; Mohamed A Hussein
Journal:  Trials       Date:  2018-01-30       Impact factor: 2.279

8.  Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.

Authors:  Yaseen M Arabi; Ayed Y Asiri; Abdullah M Assiri; Hani A Aziz Jokhdar; Adel Alothman; Hanan H Balkhy; Sameera AlJohani; Shmeylan Al Harbi; Suleiman Kojan; Majed Al Jeraisy; Ahmad M Deeb; Ziad A Memish; Sameeh Ghazal; Sarah Al Faraj; Fahad Al-Hameed; Asim AlSaedi; Yasser Mandourah; Ghaleb A Al Mekhlafi; Nisreen Murad Sherbeeni; Fatehi Elnour Elzein; Abdullah Almotairi; Ali Al Bshabshe; Ayman Kharaba; Jesna Jose; Abdulrahman Al Harthy; Mohammed Al Sulaiman; Ahmed Mady; Robert A Fowler; Frederick G Hayden; Abdulaziz Al-Dawood; Mohamed Abdelzaher; Wail Bajhmom; Mohamed A Hussein
Journal:  Trials       Date:  2020-01-03       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.